David Planchard

18PUBLICATIONS
273CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsPredictive and prognostic markersCancer geneticsHistorical, comparative and typological linguistics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Jul 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung Cancer.

|Apr 07, 2026
Retreatment with First-Generation Selective RET Inhibitors in RET-Rearranged NSCLC Pretreated with Selpercatinib or Pralsetinib: Results from the RET-MAP Registry.

Arianna Marinello, Julia K Rotow, Meghanne Lomibao

|Mar 04, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumors.

Alison M Schram, John J Park, Antoine Italiano

|Jan 31, 2026
First Line and Treatment Sequencing in EGFR-Mutated Metastatic NSCLC: What is Right for Which Patient?

Pamela Abdayem, Claudia Parisi, David Planchard

|Sep 09, 2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B).

James Chih-Hsin Yang, Mengzhao Wang, Ludovic Doucet

|Apr 16, 2025
<i>BRAF</i> Kinase Domain Duplication as a Potential On-Target Resistance Mechanism After Dabrafenib-Trametinib Therapy in a Patient With <i>BRAF</i><sup>V600E</sup>-Mutated Lung Adenocarcinoma.

Pierre de Priester, Lodovica Zullo, Damien Vasseur

Pageof 3

Frequent Collaborators

7 joint publications

Benjamin Besse

5 joint publications

Pasi A Jänne

4 joint publications

Damien Vasseur

4 joint publications

Antoine Italiano